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Abstract 
Background: Hyperkalemia  is a common medical emergen- 
cy that may result in serious cardiac arrhythmias. Standard 
therapy with insulin plus glucose reliably lowers the serum 
potassium concentration ([K+]) but carries the risk of hypo- 
glycemia. This study examined whether an intravenous glu- 
cose-only bolus lowers serum [K+] in stable, nondiabet- 
ic, hyperkalemic patients and compared this intervention 
with insulin-plus-glucose therapy. Methods: A randomized, 
crossover study was conducted in 10 chronic hemodialysis 
patients who were prone to hyperkalemia. Administration of 
10 units of insulin with 100 ml of 50% glucose (50 g) was 
compared with the administration of 100 ml of 50% glucose 
only. Serum [K+] was measured up to 60 min. Patients were 
monitored for hypoglycemia and EKG changes.   Results: 
Baseline serum [K+] was 6.01 ± 0.87 and 6.23 ± 1.20 mmol/l 
in the insulin and glucose-only groups, respectively (p = 
0.45). At 60 min, the glucose-only group had a fall in [K+] of 
0.50 ± 0.31 mmol/l (p < 0.001). In the insulin group, there was 
a fall of 0.83 ± 0.53 mmol/l at 60 min (p < 0.001) and a lower 
serum [K+] at that time compared to the glucose-only group 
(5.18 ± 0.76 vs. 5.73 ± 1.12 mmol/l, respectively; p = 0.01). In 
the glucose-only group, the glucose area under the curve 
(AUC) was greater and the insulin AUC was smaller. Two pa- 
tients in the insulin group developed hypoglycemia. Conclu- 
sion: Infusion  of a glucose-only bolus caused a clinically sig- 
nificant decrease in serum [K+] without any episodes of hy- 
poglycemia. 
 
 
 
 
Introduction 
 
Hyperkalemia is a frequently encountered medical 
emergency that can lead to life-threatening cardiac ar- 
rhythmias and therefore requires rapid and effective 
treatment. In hospitalized patients, hyperkalemia is often 
seen in individuals who are older, have impaired renal 
function, or are being treated with potassium supplemen- 
tation or drugs which block the renin-angiotensin-aldo- 
sterone system [1, 2]. The principles of management in- 
volve protecting the heart, shifting potassium into cells, 
eliminating potassium from the body and treating the un- 
derlying causes of the hyperkalemia. 
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 Several aspects of the emergency treatment remain 
controversial, although regular (soluble) insulin plus glu-
cose is usually recommended as first-line therapy in the 
acute management. β 2 -Agonists may lower serum potas-
sium (K+) to a similar degree as insulin, but around one 
third of patients have a decline in serum K + that is <0.5 
mmol/l, and therefore using these agents as monotherapy 
is not recommended  [3] . The doses of β 2 -agonists re-
quired to lower serum K + are severalfold higher than 
those used in acute asthma, leading to safety concerns, 
especially in patients who may also have cardiac disease. 
Sodium bicarbonate is recommended in the acute setting 
only if associated with a severe degree of acidosis  [4] . Cat-
ion exchange resins do not significantly increase potas-
sium excretion in the acute setting  [5, 6] and have been 
associated with instances of colonic necrosis when used 
in combination with sorbitol  [7–9] . They can therefore no 
longer be considered to be part of the standard treatment 
for acute hyperkalemia  [3, 10, 11] .
 Insulin causes a shift in K + into cells by activating NHE-
1, the Na + /H + exchanger, in cell membranes  [12] . The 
subsequent entry of Na + into the cell activates Na + /K + -
ATPase, which causes the exit of 3 Na + and the entry of 
2 K + with each cycle of the pump. In this way, insulin ther-
apy rapidly and reliably lowers serum [K + ], but this comes 
at the cost of frequent episodes of hypoglycemia, even 
when glucose is given concurrently to try and prevent this 
complication  [13–16] . Hypoglycemia is a serious and 
common adverse effect of insulin therapy and may mani-
fest several hours after insulin administration  [17, 18] .
 While earlier studies in various settings have demon-
strated that oral or intravenous glucose loading can lower 
serum [K + ]  [19–22] , this has never been adopted as a 
component of the therapy for the emergency treatment of 
hyperkalemia. There have been concerns that the admin-
istration of an intravenous glucose bolus without insulin 
might not elicit sufficient release of endogenous insulin 
to cause a rapid, reliable and clinically useful degree of 
potassium shift into cells  [3, 23, 24] . Some uremic pa-
tients may have a decreased early insulin response  [25] , 
and acutely ill patients may have α-adrenergic activation 
causing impaired pancreatic insulin release  [26] . Another 
concern is that the administration of hypertonic glucose 
may paradoxically worsen the hyperkalemia by causing a 
shift of potassium out of cells  [27–29] . Solvent drag of 
potassium-rich intracellular water into the extracellular 
compartment and increased leakage of potassium out of 
cells effected by the hypertonicity have been suggested as 
possible mechanisms for this phenomenon  [29] .
 We studied the question of shifting potassium into cells 
in a group of hyperkalemic patients on chronic hemodialy-
sis (HD) and compared the efficacy and safety of a glucose 
bolus with that of standard insulin-glucose therapy. Many 
of the studies which have informed the current treatment 
of hyperkalemia have been conducted in similar groups of 
patients with end-stage renal disease (ESRD). While these 
patients all have some degree of insulin resistance with re-
spect to glucose homeostasis  [30–32] , the other actions of 
insulin are maintained, including the shift of potassium 
into cells  [33] .
 Materials and Methods 
 We undertook this clinical trial in ESRD patients who were on 
thrice-weekly HD at the Renal Unit of Tygerberg Hospital in Cape 
Town, South Africa. Ethics approval was obtained from the Stel-
lenbosch University Health Research Ethics Committee (reference 
No. M07/10/060). All participants gave written, informed consent. 
The trial adhered to the Declaration of Helsinki and was registered 
in the Pan African Clinical Trials registry before commencement 
(reference No. ATMR2009100001631792).
 Participants 
 The study population of 10 individuals was recruited from stable 
nondiabetic patients who had been on chronic HD for at least 3 
months. Participants prone to developing hyperkalemia were iden-
tified from their last 3 sets of routine blood results, with all having 
serum [K + ] exceeding 5.0 mmol/l before dialysis in each of the tests.
 Study Design 
 A randomized, crossover, double-blind study was conducted 
with a washout period of at least 1 week between the two interven-
tions for each participant ( fig. 1 ). Simple randomization to receive 
insulin plus glucose or the glucose-only bolus as the first treatment 
was done using a computer-generated random number sequence. 
Allocation concealment was achieved with the use of sequentially 
numbered, opaque, sealed envelopes. An independent assistant 
prepared syringes with either 10 units of regular insulin or with an 
equivalent volume of saline. The participants, the treating doctor 
and the dialysis staff were blinded to the treatment administered.
 Study Procedures 
 Participants were all studied in the non-fasting state on dialysis 
days following their longest interdialytic period. All blood samples 
were drawn from a cannulated arteriovenous fistula or a temporary 
dialysis catheter, were centrifuged promptly and processed by a sin-
gle, internationally accredited laboratory. Potassium concentrations 
were measured by ion-selective electrode, glucose was measured by 
the hexokinase method and insulin by immunoassay on Roche/Hi-
tachi Cobas ® c 501 and c 601 systems. Baseline samples for potas-
sium, glucose and insulin levels were taken. Blood pressure, heart 
rate and weight were documented, and a 12-lead EKG tracing re-
corded. The insulin, and the saline in the case of the controls, was 
injected into a 50-ml bag of 50% dextrose and infused rapidly at time 
0. This was followed immediately by the infusion of a second 50-ml 
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bag of 50% dextrose and then by 50 ml of normal saline to flush the 
giving set. The total dose of glucose administered was 50 g and the 
infusion of the solutions took 4–5 min. Blood samples for potassi-
um, glucose and insulin levels were repeated after 10, 20, 40 and 60 
min. Blood pressure and heart rate measurements were repeated at 
the same time points. Bedside blood glucose measurements were 
done at each time point using a Roche Accu-Chek Active ® glucom-
eter and participants were monitored for symptoms of hypoglyce-
mia. If blood glucose fell <3.0 mmol/l or symptoms of hypoglycemia 
developed at any point, an additional 50-ml bolus of 50% dextrose 
was infused. The EKG was repeated after 60 min. EKGs were read 
by two of the authors (M.-Y.C. and M.R.D.) to identify changes typ-
ical of hyperkalemia, namely tall, peaked T waves, flattened or ab-
sent P waves and widening of the QRS complex.
 Outcomes 
 The primary outcomes of interest were the magnitude of the 
fall in serum [K + ] from baseline values and the difference in serum 
[K + ] at 60 min between the two treatment groups. The secondary 
outcomes related to safety, namely episodes of hypoglycemia and 
EKG abnormalities.
 Statistical Methods 
 Data are reported as means ± SD and statistical significance was 
set at p < 0.05.
Stable chronic HD patients screened
Inclusion criteria: 3 prior serum [K+] >5.0 mmol/l
Exclusion criteria: diabetic patients
11 participants enrolled
10 units insulin plus 100 ml 50% glucose (n = 5)
10 units insulin plus 100 ml 50% glucose (n = 5)
100 ml 50% glucose bolus only (n = 5)
Outcomes evaluated (10 participants/group)
Primary
Fall in serum [K+] from baseline; difference in serum 
[K+] at 60 min between groups
Secondary
Episodes of hypoglycemia
100 ml 50% glucose bolus only (n = 5)
1 participant withdrawn
after serious adverse event
 Fig. 1. Study flow diagram: in this crossover design, 10 participants completed both arms of the study and could be evaluated. The first 
treatment for each participant was randomly assigned, and participants and medical staff were blinded to the treatment administered. 
Each participant had a washout period of at least 1 week between treatment arms. 
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  Results 
 The baseline characteristics of the participants are 
summarized in  table 1 . The 10 participants who complet-
ed the study had a mean age of 40.2 years (range 20–54). 
There were equal numbers of males and females. There 
were 6 participants who were being treated with atenolol 
for hypertension during the study.
 At baseline, the mean serum [K + ] was 6.01 ± 0.87 
mmol/l in the insulin group and 6.23 ± 1.20 mmol/l in the 
glucose-only group (p = 0.449). At 60 min, the glucose-
only group had a fall in [K + ] of 0.50 ± 0.31 mmol/l (p < 
0.001) while in the insulin group there was a fall from 
baseline of 0.83 ± 0.53 mmol/l (p < 0.001). The insulin 
group had a lower serum [K + ] at 60 min as compared to 
the glucose-only group (5.18 ± 0.76 vs. 5.73 ± 1.12 mmol/l, 
respectively; p < 0.010;  fig. 2 ).
 There was no difference in the fall in mean serum [K + ] 
at 60 min between participants who were on atenolol as 
compared with those who were not (0.66 vs. 0.60 mmol/l, 
respectively; p = 0.645).
 Analysis of individual patient data revealed that 9 of 
the 10 participants in the glucose-only group had a fall in 
serum [K + ] at 60 min while 1 participant was unchanged 
(the fall from baseline values ranged from 0.0 to 1.1 
mmol/l). All the participants in the insulin group had a 
lower value at 60 min (differences ranged from 0.1 to 2.0 
mmol/l). At the earliest time point (10 min), there was 1 
participant in the glucose group with a higher serum [K + ] 
than at baseline (an increase of 0.2 mmol/l), while there 
were 3 participants with a rise in serum [K + ] at this time 
point (mean increase of 0.4 mmol/l) in the insulin group.
 Plasma glucose concentrations ( fig. 3 ) were similar at 
baseline in the insulin and glucose-only groups (5.57 ± 
2.01 vs. 5.08 ± 0.73 mmol/l, respectively; p = 0.500). Glu-
cose concentrations at 60 min were higher in the glucose-
only group (5.26 vs. 7.68 mmol/l; p = 0.031) but not at the 
earlier time points. The area under the curve (AUC) was 
greater in the glucose-only group with a mean AUC of 
857.8 ± 54.2 versus 731.0 ± 59.0 mmol    ·    min/l (p = 0.048).
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 Fig. 2. Serum potassium concentration versus time: values at 60 
min are significantly lower than baseline values in each treatment 
group (p < 0.001 in each case); at 60 min they are significantly 
lower in the insulin as compared to the glucose-only group (p = 
0.010). Mean values with 95% confidence intervals. 
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 Fig. 3. Plasma glucose concentration versus time: at 60 min, but 
not at any other time point, the glucose concentrations were high-
er in the glucose-only group (7.68 vs. 5.26 mmol/l, p = 0.031). 
Mean values with 95% confidence intervals. 
Table 1.  Baseline characteristics of the participants (n = 10)
Baseline characteristics Insulin-
glucose
Glucose-
only
p
values
Males, n 5 5
Mean age, years 40.2 40.2
Mean potassium, mmol/l 6.01 ± 0.87 6.23 ± 1.20 0.45
Mean glucose, mmol/l 5.57 ± 2.01 5.08 ± 0.73 0.50
Mean insulin, μU/ml 28.41 ± 32.7 21.84 ± 18.3 0.48
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 Insulin concentrations ( fig. 4 ) were similar at baseline 
(28.4 ± 32.7 μU/ml in the insulin group vs. 21.8 ± 18.3 μU/
ml in the glucose-only group, p = 0.484) but higher at 10 
min (547.5 ± 348.5 vs. 183.7 ± 128.2 μU/ml, p = 0.002), 20 
min (467.4 ± 217.0 vs. 163.4 ± 99.6 μU/ml, p < 0.001), 40 
min (200.6 ± 145.0 vs. 89.7 ± 40.0 μU/ml, p = 0.034) and 
at 60 min (92.3 ± 66.1 vs. 43.5 ± 23.4 μU/ml, p = 0.038) in 
the insulin group. The AUC was greater in the insulin 
group with a mean AUC of 17,564.1 ± 2,897.1 versus 
6,626.3 ± 1,129.9 μU    ·    min/ml (p = 0.001).
 Two participants in the insulin group developed hypo-
glycemia. Both were using atenolol. One developed symp-
tomatic hypoglycemia with a glucose concentration of 2.4 
mmol/l at 90 min and the other developed asymptomatic 
hypoglycemia with a glucose concentration of 1.4 mmol/l 
at 60 min. They received an additional 50 ml of 50% glu-
cose as per protocol. There were no episodes of hypogly-
cemia in the glucose-only group.
 One participant developed pulmonary edema shortly 
after the administration of the study medication (insulin 
plus glucose). EKG and cardiac enzymes did not reveal 
any evidence of arrhythmia, ischemia or infarction, but 
echocardiography revealed hypertensive heart disease 
with severe diastolic dysfunction. The participant was 
withdrawn from the study after this serious adverse event.
 All patients reported a warm or burning sensation at the 
site of infusion, which subsided as soon as the infusion ended.
 In 5 patients, EKG changes of hyperkalemia were pres-
ent at baseline on both arms of the study and in 1 patient 
on the occasion of the glucose arm only. Tall T waves were 
present in all of these cases, and decreases in T wave am-
plitude were observed on the 60-min EKG in all the pa-
tients after insulin administration and in 3 of the 6 patients 
after administration of the glucose-only bolus. A flat P 
wave was present in 1 patient before the glucose-only bo-
lus; this was unchanged at 60 min. No widening of the QRS 
complexes was seen.
 Discussion 
 In our study, an intravenous glucose bolus caused a 
clinically significant decrease in serum [K + ] concentra-
tion of approximately 0.5 mmol/l, without any incidents 
of hypoglycemia. These findings suggest that an intrave-
nous infusion of glucose could be considered as a thera-
peutic option in the emergency treatment of hyperkale-
mia in settings where careful monitoring for hypoglyce-
mia may not always be possible and where attending 
clinicians may prefer to avoid the risk of this serious com-
plication altogether.
This approach of using endogenously secreted insulin 
to shift K+ into cells is supported by data from a recent 
paper by Cheema-Dhadli et al.  [34] , who studied the ef-
fects of an infusion of L-lactic acid on K+ shift in rats. They 
demonstrated that the liver plays a major role in remov-
ing absorbed dietary K+ from the portal blood, thereby 
minimizing the risk of cardiac arrhythmia which might 
result if blood with a high serum K+ concentration were 
delivered to the heart. The first component of the pro-
posed mechanism is a high rate of production of L-lactic 
acid by enterocytes with subsequent lactic acid entry into 
hepatocytes on the monocarboxylic acid cotransporter 
[35]. The second is the release of insulin into the portal 
vein in response to a rise in blood glucose concentrations. 
These factors activate NHE-1 [36] and allow the entry of 
Na+ followed by its electrogenic efflux via Na+-K+-
ATPase, creating a more negative intracellular voltage 
and retaining more K+ inside hepatocytes.
 Our participants receiving insulin had higher insulin 
concentrations and a larger fall in serum K + concentra-
tion compared to those receiving glucose only. In future 
studies, it would be useful to study the effects of infusing 
larger doses of glucose to try and induce more endoge-
nous insulin release and possibly achieve a fall in K + con-
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 Fig. 4. Serum insulin concentration versus time: insulin concentra-
tions were similar at baseline in both groups (p = 0.484) but were 
higher in the insulin group at 10 (p = 0.002), 20 (p < 0.001), 40 
(p = 0.034) and 60 min (p = 0.038). The mean AUC was greater in 
the insulin group (17,564.1 vs. 6,626.3 μU     ·     min/ml, p = 0.001). 
Mean values with 95% confidence intervals. 
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 centration which is comparable to that seen when insulin 
is administered.
 Hypoglycemia remains a common complication of in-
sulin therapy. In a recent Japanese hospital-based survey 
 [37] , hypoglycemia was associated with serious complica-
tions, including QT prolongation and new-onset atrial fi-
brillation. This, at least in part, might be related to the 
excessive release of sympathetic hormones in response to 
the hypoglycemia. In studies of insulin therapy for the 
treatment of hyperkalemia, hypoglycemia has been docu-
mented in as many as 75% of participants ( table 2 ). There 
appear to be fewer hypoglycemic events when the glucose 
dose is larger, when the insulin bolus is given after the 
glucose infusion rather than before it and when the treat-
ment is given as a constant infusion over 60 min rather 
than as a bolus. Careful clinical monitoring and repeated 
measurements of blood glucose are recommended for 
several hours after insulin therapy  [17, 18] .
 Our protocol specified a higher glucose/insulin ratio 
(50 g of glucose/10 units of insulin) than those used in the 
other studies summarized in  table 2 , but despite this there 
were hypoglycemic episodes in 2 of 10 patients. It is pos-
sible that giving the insulin after first infusing all of the 
glucose may have reduced the incidence of this complica-
tion.
 The infusion of large amounts of hypertonic glucose 
without insulin carries the theoretical risk of increasing se-
rum [K + ] via the high serum osmolality, which may cause 
potassium-rich intracellular water to flow out of cells. In 
the study by Conte et al.  [29] , hypertonic saline caused an 
increase in serum [K + ] independent of pH, bicarbonate 
concentration, anion gap, insulin concentration and uri-
nary adrenaline and noradrenaline levels. An earlier study 
by Goldfarb et al.  [27] examined the effect of rapid infu-
sions of hypertonic glucose on serum [K + ] and found that 
hyperkalemia developed in subjects with combined insulin 
and aldosterone deficiency but not in normal volunteers or 
Table 2.  Risk of hypoglycemia with insulin therapy for hyperkalemia
Study and participants (n) Glucose,
g
Insulin,
units
Glu/Ins
ratio
Hypoglycemia,
n (%)
ΔK+ Details
Blumberg et al. [13] 1988
ESRD (10)
20 20 1 5 (50) 0.92 Insulin-glucose infusion at 5 mU/kg/min 
insulin for 60 min
Lens et al. [14] 1989
ESRD/AKI (10)
40 10 4 2 (20) 1.0 Glucose over 15 min and insulin bolus
Allon & Copkney [15] 1990
ESRD (12)
25 10 2.5 9 (75) 0.65 Insulin bolus then glucose over 5 min
Ljutic & Rumboldt [38] 1993
ESRD (9)
25 10 2.5 1 (11) 0.76 Glucose over 5 min then insulin bolus
Allon & Shanklin [39] 1996
ESRD (8)
60 20 3 0 (0) 0.85 Insulin-glucose infusion at 5 mU/kg/min 
insulin for 60 min
Kim [40] 1996
ESRD (8)
40 20 2 0 (0) 0.6 Insulin-glucose infusion at 5 mU/kg/min 
insulin for 60 min
Ngugi et al. [41] 1997
AKI/CKD (10)
25 10 2.5 2 (20) 1.14 Glucose over 15 min then insulin bolus
Mahajan et al. [16] 2001
ESRD (11)
25 12 2.1 1 (9) 0.47 Insulin-glucose infusion at 5 mU/kg/min 
insulin for 30 min
Chothia et al., 20141
ESRD (10)
50 10 5 2 (20) 0.83 Insulin-glucose over 2 – 3 min then glucose 
over 2 – 3 min
 Data were extracted from studies on the treatment of hyperkalemia with an insulin-glucose arm where data on hypoglycemia were 
reported. Dosages of insulin and glucose, and changes in plasma or serum (K+) are as at the end of 60 min. The Glu/Ins ratio refers to 
the dose of glucose in grams and that of insulin in international units. AKI = Acute kidney injury; CKD = chronic kidney disease.
1 Data from the present study.
6
in diabetics with insulin deficiency alone. None of our par-
ticipants had a rise in serum [K + ] at 60 min compared to 
baseline values. At the earliest time point, when the effect 
of the hypertonic infusion would be expected to be maxi-
mal, there were more patients in the insulin than in the 
glucose-only group with a rise in serum [K + ].
 Another concern is that hypertonic solutions, with or 
without insulin, rapidly expand the extracellular fluid 
compartment, increasing the risk of pulmonary edema in 
patients with heart disease. This complication was seen in 
1 of our participants after receiving the insulin-glucose 
combination.
 The efficacy and safety of glucose-only boluses in 
treating hyperkalemia in acutely ill patients needs further 
investigation, and our data cannot be generalized to these 
patients. It is possible that in situations where α-adrenergic 
stimulation might be increased, e.g. in critically ill pa-
tients, this would suppress endogenous pancreatic insulin 
release and a glucose-only regimen might not be effective 
in reducing serum [K + ].
 Conclusion 
 In stable, nondiabetic HD patients an intravenous glu-
cose bolus caused a clinically significant decrease in se-
rum [K + ] of 0.5 mmol/l. This provides an additional treat-
ment option in the emergency treatment of hyperkalemia 
without the risk of inducing hypoglycemia. Further stud-
ies are needed to investigate the role of this intervention 
in acutely ill patients.
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